cintirorgon

RORgamma Agonist

Also Known As:

2H-1,4-Benzoxazine-2-propanoic acid, 6-(3-(difluoromethoxy)-5-fluorophenyl)-3,4-dihydro-alpha,alpha-dimethyl-4-((3-(trifluoromethyl)phenyl)sulfonyl)-, (2S)-; 3-((2S)-6-(3-(Difluoromethoxy)-5-fluorophenyl)-4-((3-(trifluoromethyl)phenyl)sulfonyl)-3,4-dihydro-2H-1,4-benzoxazin-2-yl)-2,2-dimethylpropanoic acid; LYC-55716

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Beijnen, Jos H: 2 articles (08/2022 - 01/2022)
2.	Heydari, Paniz: 2 articles (08/2022 - 01/2022)
3.	Li, Wenlong: 2 articles (08/2022 - 01/2022)
4.	Schinkel, Alfred H: 2 articles (08/2022 - 01/2022)
5.	Sparidans, Rolf W: 2 articles (08/2022 - 01/2022)
6.	Hu, Xiao: 2 articles (01/2021 - 01/2019)
7.	Lebre, Maria C: 1 article (08/2022)
8.	Lehutová, Daniela: 1 article (08/2022)
9.	Wang, Jing: 1 article (08/2022)
10.	Aicher, Thomas D: 1 article (01/2021)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2022 - "Cintirorgon (LYC-55716), a first-in-class, small-molecule, oral selective RORγ agonist, has been developed as a new immuno-oncology drug for solid tumors. " 01/01/2021 - "LYC-55716 decreases tumor growth and enhances survival in preclinical tumor models and was nominated as a clinical development candidate for evaluation in patients with solid tumors." 01/05/2022 - "Cintirorgon (LYC-55716) is a promising first-in-class antitumor agent as a RORγ agonist in the treatment against various types of cancer. " 01/01/2019 - "A phase 1 study evaluated the safety and tolerability of LYC-55716 (cintirorgon), a first-in-class, oral, small-molecule RORγ agonist in adults with relapsed/refractory metastatic cancer. "
2.	Ovarian Neoplasms (Ovarian Cancer) 01/01/2019 - "These data support the safety and tolerability of LYC-55716 and selection of 450 mg BID dose for a phase 2a study assessing LYC-55716 clinical activity, safety, and biomarkers in patients with NSCLC, head and neck, gastroesophageal, renal cell, urothelial, and ovarian cancers."

Related Drugs and Biologics

1.	cintirorgon
2.	Biomarkers (Surrogate Marker)
3.	Antineoplastic Agents (Antineoplastics)